What is Rufinamid used for?

Rufinamid is indicated for Lennox-Gastaut syndrome.

Rufinamid is developed by University of Zurich.

What development phase is Rufinamid in?

Rufinamid is FDA-approved (marketed).

What are the side effects of Rufinamid?

Common side effects include Headache, Dizziness, Fatigue, Nausea, Somnolence, Diplopia.

Last reviewed 2026-04-20 · How we verify

Rufinamid

University of Zurich · FDA-approved active Small molecule

At a glance

Generic name	Rufinamid
Sponsor	University of Zurich
Target	Carbonic anhydrase 5A, mitochondrial, Sodium channel alpha subunit
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

Lennox-Gastaut syndrome

Common side effects

Headache
Dizziness
Fatigue
Nausea
Somnolence
Diplopia
Tremor
Nystagmus
Blurred Vision
Vomiting
Ataxia
Upper Abdominal Pain

Key clinical trials

Effect of Oral Rufinamide and Oxcarbazepine on Nerve Excitability, Hyperalgesia, Allodynia and Flare Reaction Compared to Placebo. A Monocenter, Randomized, Double-blind, Cross-over Study

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Rufinamid CI brief — competitive landscape report
Rufinamid updates RSS · CI watch RSS
University of Zurich portfolio CI